Eurofins Scientific SEERFSF +2.40%78 Debt-to-EBITDA is 2.92 as of Dec. 2025, which is 2% above its 10-year median of 2.87. GuruFocus rates ERFSF with a GF Score™ of 78/100 and a GF Value™ of $77.01 (Fairly Valued). The stock has 6 warning signs investors should review. Among 113 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 58.41% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Eurofins Scientific SE's Debt-to-EBITDA or its related term are showing as below:
ERFSF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.63 Med: 2.87 Max: 4.81
Current: 2.89
During the past 13 years, the highest Debt-to-EBITDA Ratio of Eurofins Scientific SE was 4.81. The lowest was 1.63. And the median was 2.87.
ERFSF's Debt-to-EBITDA is ranked worse than 58.41% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.3
vs ERFSF: 2.89
Eurofins Scientific SE (OTCPK:ERFSF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Eurofins Scientific SE Debt-to-EBITDA Related Terms
Eurofins Scientific SE Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Eurofins Scientific SE's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERFSF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Eurofins Scientific SE (ERFSF) has a Debt-to-EBITDA of 2.92 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Eurofins Scientific SE. This is near median its historical median of 2.87. Over the past decade, Eurofins Scientific SE's Debt-to-EBITDA has ranged from 1.63 to 4.81. According to the industry distribution chart, Eurofins Scientific SE ranks #66 out of 113 companies in the Medical Diagnostics & Research industry, placing it in the top 58.4%.
Is Eurofins Scientific SE's Debt-to-EBITDA too high?
Eurofins Scientific SE's current Debt-to-EBITDA of 2.92 is near median its 10-year median of 2.87. Over the past 10 years, this metric has ranged from a low of 1.63 to a high of 4.81. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.30. Eurofins Scientific SE's value of 2.92 is 27% above this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #66 out of 113 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #66 out of 113 companies for Debt-to-EBITDA. This places Eurofins Scientific SE in the lower half of its industry. The industry median Debt-to-EBITDA is 2.30. Eurofins Scientific SE's value of 2.92 is 27% above this benchmark. Historically, Eurofins Scientific SE's own Debt-to-EBITDA has ranged from 1.63 to 4.81 over the past decade. While the company's 10-year median is 2.87 vs. the industry median of 2.30, Eurofins Scientific SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.30, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Debt-to-EBITDA of 2.92 is 27% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Eurofins Scientific SE. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Debt-to-EBITDA is 2.92, which is near median its own 10-year median of 2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $77.01, compared to a current price of $78.84 — trading 2.4% above its estimated fair value. The current Debt-to-EBITDA is 2.92, which is near median its 10-year median of 2.87 and 27% above the Medical Diagnostics & Research industry median of 2.30. Eurofins Scientific SE's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Debt-to-EBITDA is 2.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $78.84 is trading 2.4% above its estimated GF Value™ of $77.01.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
Debt-to-EBITDA: 2.92 (near median its 10-year median of 2.87)
GF Value™: $77.01 vs. price of $78.84 (2.4% above fair value)
Industry Position: 27% above the Medical Diagnostics & Research median (#66 of 113)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
78GF Score
Get the complete analysis for ERFSF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
